Co-Diagnostics Begins Shipments To Support India TB Studies<\/p>\n
These materials are necessary to begin clinical performance studies of the TB test on the PCR platform, as the company completes final steps toward initiating those studies in the near term.<\/p>\n
Last week, Co-Diagnostics signed an agreement for CoSara Diagnostics Pvt. Ltd, to expand its commercial and distribution<\/a> territory across South Asia to include Bangladesh, Pakistan, Nepal, and Sri Lanka.<\/p>\n WHO Guidance Aligns With Company’s TB Testing Approach<\/p>\n The company’s PCR testing platform and NPOC TB test kit are already aligned with this new guidance.<\/p>\n Co-Diagnostics CEO Dwight Egan remarked, “We are pleased that our foresight in designing the Co-Dx PCR testing platform and TB test for broad accessibility in point-of-care and near-point-of-care settings, and to be operated with either sputum or tongue swab samples, is consistent with the direction of the WHO’s recommendation.”<\/p>\n Mr. Egan continued, “The Co-Dx PCR MTB test has continued to generate encouraging third-party preclinical results, supporting further clinical evaluation.”<\/p>\n Regulatory Progress In India For PCR Pro Instrument<\/p>\n In October, Co-Diagnostics signed a definitive agreement with Arabian Eagle to establish CoMira Diagnostics, a Saudi joint venture that will manufacture, assemble, and distribute Co-Dx technologies, including the company’s next-generation PCR platform<\/a>.<\/p>\n The partnership supports Saudi Vision 2030 by focusing on healthcare innovation, industrial diversification, and localization of technology.<\/p>\n CODX Stock Price Activity: Co-Diagnostics shares were up 7.93% at $2.45 during premarket trading on Wednesday, according to Benzinga Pro data<\/a>.<\/p>\n Image via Shutterstock<\/p>\n